The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Associations between treatment-emergent symptoms and early discontinuation of aromatase inhibitor (AI) therapy.
 
Kunal C. Kadakia
No Relationships to Disclose
 
Claire Frances Snyder
Stock and Other Ownership Interests - Express Scripts; Immunomedics; Merck; Oncolytics
Consulting or Advisory Role - Walgreens (Inst)
Research Funding - Genentech (Inst); WellPoint (Inst)
 
Kelley M Kidwell
No Relationships to Disclose
 
Nicholas J. Seewald
No Relationships to Disclose
 
Anna Maria Storniolo
Employment - Lilly (I)
 
David A. Flockhart
Consulting or Advisory Role - Boston Biomedical; Quest Diagnostics
Research Funding - Novartis; Pfizer
 
Janet S Carpenter
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - 3rd UK Breast Cancer Meeting, Londong; Lilly
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.; Title: Circulating tumor cell capturing techniques and devices. Original application no. 61/593,092.; Title: Diagnosis and treatment of breast cancer. Original application no. 61/079,642; Revised application no. 61/224,310.
 
Vered Stearns
Research Funding - Abbvie; Celgene; MedImmune; Merck; Novartis; Pfizer; Puma Biotechnology
 
Norah Lynn Henry
Research Funding - BioMarin; Celldex; Sanofi
Travel, Accommodations, Expenses - Celldex